Edition:
United Kingdom

Valneva SE (VLS.PA)

VLS.PA on Paris Stock Exchange

3.63EUR
18 Jan 2019
Change (% chg)

€-0.08 (-2.16%)
Prev Close
€3.71
Open
€3.68
Day's High
€3.72
Day's Low
€3.56
Volume
109,412
Avg. Vol
86,834
52-wk High
€4.19
52-wk Low
€3.01

Chart for

About

Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and... (more)

Overall

Beta: 1.88
Market Cap(Mil.): €226.54
Shares Outstanding(Mil.): 77.58
Dividend: --
Yield (%): --

Financials

  VLS.PA Industry Sector
P/E (TTM): -- 69.71 33.71
EPS (TTM): -0.19 -- --
ROI: -8.43 8.99 14.48
ROE: -13.92 10.13 15.99

Emergent-Valneva Zika vaccine clears early trial

A vaccine to prevent infections caused by the deadly mosquito-borne Zika virus induced immune response and was found to be safe in an early stage trial, Emergent BioSolutions Inc and partner Valneva SE said on Monday.

19 Nov 2018

Emergent-Valneva Zika vaccine clears early trial

Nov 19 A vaccine to prevent infections caused by the deadly mosquito-borne Zika virus induced immune response and was found to be safe in an early stage trial, Emergent BioSolutions Inc and partner Valneva SE said on Monday.

19 Nov 2018

Earnings vs. Estimates